Andrew Norris

Senior Director, Research BCN Biosciences

Seminars

Wednesday 17th September 2025
Panel Discussion: Reducing Non-Responsiveness of RAS-Targeted Therapies by Delving into Mutation & Tissue Specific Impacts to Improve Drug Efficac
1:30 pm

• Uncovering factors within the tumor microenvironment which may result in non-responsiveness to

RAS-targeted therapies

• How do tissue specific interactions influence efficacy of RAS-targeting drugs?

• How do you successfully overcome or delay resistance to RAS-targeting therapies?

Thursday 18th September 2025
Improving Therapeutic Efficacy by Targeting the MAPK Pathway to Disrupt Tumor Growth & Reduce Oncogenesis
4:00 pm
  • How to target specific MAPK substrates that are critical for tumor growth without disrupting broader cellular functions
  • How does targeting upstream and downstream regulators of RAS signaling enhance drug efficacy?
  • Addressing how alternative signaling pathways, particularly the PI3K/AKT pathway, contribute to resistance against MAPK-targeted therapies
Andrew Norris